{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:30:39Z","timestamp":1794022239533,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM135399"],"award-info":[{"award-number":["GM135399"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["HL175251"],"award-info":[{"award-number":["HL175251"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["HL151924"],"award-info":[{"award-number":["HL151924"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.atherosclerosis.2025.120404","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:25:52Z","timestamp":1749756352000},"page":"120404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Empagliflozin restores cardiac metabolism and suppresses immune activation in acute myocardial infarction"],"prefix":"10.1016","volume":"407","author":[{"given":"Nikolaos","family":"Mylonas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota Efstathia","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Siokatas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis V.","family":"Kostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ourania","family":"Tsitsilonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-834X","authenticated-orcid":false,"given":"Konstantinos","family":"Drosatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Andreadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2025.120404_bib1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-reduced","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib3","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/cvr\/cvad157","article-title":"Empagliflozin improves cardiac energetics during ischaemia\/reperfusion by directly increasing cardiac ketone utilization","volume":"119","author":"Chase","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib4","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib5","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","article-title":"Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects","volume":"8","author":"Andreadou","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/ars.2019.7923","article-title":"Chronic empagliflozin treatment reduces myocardial infarct size in nondiabetic mice through STAT-3-mediated protection on microvascular endothelial cells and reduction of oxidative stress","volume":"34","author":"Nikolaou","year":"2021","journal-title":"Antioxidants Redox Signal"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib7","article-title":"Empagliflozin in acute myocardial infarction reduces no-reflow and preserves cardiac function by preventing endothelial damage","author":"Nikolaou","year":"2024","journal-title":"JACC (J Am Coll Cardiol): Basic to Translational Science"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000791","article-title":"Mineralocorticoid receptor pathway is a key mediator of carfilzomib-induced nephrotoxicity: preventive role of eplerenone","volume":"6","author":"Efentakis","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1161\/CIRCULATIONAHA.120.047420","article-title":"Cardiomyocyte Kr\u00fcppel-like factor 5 promotes de novo ceramide biosynthesis and contributes to eccentric remodeling in ischemic cardiomyopathy","volume":"143","author":"Hoffman","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvaf040","article-title":"Cardiac ischaemia\/reperfusion in pigs and mice increases cardiomyocyte Kr\u00fcppel-like factor 5 that aggravates tissue injury and remodelling","author":"Mylonas","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00062752-200301000-00004","article-title":"Structure, organization, and function of glycosphingolipids in membrane","volume":"10","author":"Hakomori","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109655","article-title":"UDP-Glucose sensing P2Y14R: a novel target for inflammation","author":"Zhang","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121805","article-title":"Upregulation of P2Y14 receptor in neutrophils promotes inflammation after myocardial ischemia\/reperfusion injury","volume":"326","author":"Li","year":"2023","journal-title":"Life Sci"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/mol.115.098756","article-title":"UDP-sugars as extracellular signaling molecules: cellular and physiologic consequences of P2Y14 receptor activation","volume":"88","author":"Lazarowski","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib15","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.3390\/ijms20246362","article-title":"Vascular diseases and gangliosides","volume":"20","author":"Sasaki","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib16","first-page":"62","article-title":"The enigmata of cardioprotection with SGLT2 inhibition","author":"Heusch","year":"2025","journal-title":"American College of Cardiology Foundation Washington DC"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib17","article-title":"Effect of empagliflozin on blood volume redistribution in patients with chronic heart failure and reduced ejection fraction: an analysis from the empire HF randomized clinical trial","volume":"15","author":"Omar","year":"2022","journal-title":"Circulation: Heart Fail"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/db21-0721","article-title":"Randomized controlled trial of the hemodynamic effects of empagliflozin in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE trial","volume":"71","author":"Wolsk","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCRESAHA.124.324823","article-title":"SGLT2 inhibitors act independently of SGLT2 to confer benefit for HFrEF in mice","volume":"135","author":"Berger","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","article-title":"Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2","volume":"147","author":"Chen","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib21","first-page":"575","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC (J Am Coll Cardiol): Basic to Translational Science"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/CIRCRESAHA.120.317933","article-title":"Targeting mitochondria-inflammation circuit by \u03b2-hydroxybutyrate mitigates HFpEF","volume":"128","author":"Deng","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib23","first-page":"1","author":"Ma","year":"2022"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113677","article-title":"Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats","volume":"170","author":"Aragon-Herrera","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib25","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","article-title":"Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials","volume":"67","author":"Stone","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib26","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jacc.2016.01.073","article-title":"Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction","volume":"67","author":"Westman","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027600","article-title":"Impact of reperfusion on temporal immune cell dynamics after myocardial infarction","volume":"12","author":"Zhang","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib28","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1126\/science.1175202","article-title":"Identification of splenic reservoir monocytes and their deployment to inflammatory sites","volume":"325","author":"Swirski","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib29","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","author":"Usman","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/cvr\/cvab036","article-title":"Immuno-metabolic interfaces in cardiac disease and failure","volume":"118","author":"Bertero","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib32","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.atherosclerosis.2025.120404_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00228-023-03582-5","article-title":"Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm parallel-group, controlled trial","volume":"80","author":"Khiali","year":"2024","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025013024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025013024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:08:09Z","timestamp":1778944089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025013024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"alternative-id":["S0021915025013024"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120404","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin restores cardiac metabolism and suppresses immune activation in acute myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120404"}}